

# Megan Melody

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3316489/publications.pdf>

Version: 2024-02-01

13  
papers

56  
citations

2258059

3  
h-index

1720034

7  
g-index

13  
all docs

13  
docs citations

13  
times ranked

92  
citing authors

#	ARTICLE	IF	CITATIONS
1	Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. Immunotherapy, 2020, 12, 1121-1126.	2.0	18
2	Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 324-328.	0.4	13
3	Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 312-315.	0.4	5
4	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 141-146.	0.9	5
5	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. Leukemia and Lymphoma, 2022, 63, 1363-1368.	1.3	4
6	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. European Journal of Haematology, 2021, 107, 48-53.	2.2	3
7	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2022, 63, 199-204.	1.3	3
8	Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction. Leukemia Research Reports, 2020, 14, 100228.	0.4	2
9	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	2
10	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). Blood, 2019, 134, 5343-5343.	1.4	1
11	Follicular lymphoma associated paraneoplastic myositis. Clinical Case Reports (discontinued), 2020, 8, 2003-2006.	0.5	0
12	23-Year-Old Female With Right-Sided Weakness and Aphasia. Mayo Clinic Proceedings, 2021, 96, 1634-1638.	3.0	0
13	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. Blood, 2019, 134, 5610-5610.	1.4	0